LOGIN  |  REGISTER
Astria Therapeutics

NeuroPace to Participate in Upcoming Investor Conferences

August 24, 2023 | Last Trade: US$12.01 0.41 -3.30
  • Wells Fargo 2023 Healthcare Conference 
  • Morgan Stanley 21st Annual Global Healthcare Conference 
  • Lake Street Capital Markets 7th Annual Best Ideas Growth Conference 

MOUNTAIN VIEW, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced its participation in the following upcoming investor conferences:

  • Management will host 1x1 meetings at the Wells Fargo 2023 Healthcare Conference on Thursday, September 7, 2023, in Everett, MA.
  • Joel Becker, CEO, and Rebecca Kuhn, CFO, will participate in a fireside chat discussion and host 1x1 meetings at the Morgan Stanley 21st Annual Global Healthcare Conference at 9:30 AM ET on Wednesday, September 13, 2023, in New York, NY.
  • Management will host 1x1 meetings at the Lake Street Capital Markets 7th Annual Best Ideas Growth Conference on Thursday, September 14, 2023, in New York, NY

About NeuroPace, Inc.

Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page